Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 19/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7325416 | 1.00 | KIF11 (1.00) | KIF11CYP1A2CYP2C19HIF1A | |
| SCHEMBL7317498 | 0.91 | KIF11 (1.00) | KIF11CYP1A2CYP2C19HIF1A | |
| SCHEMBL3473170 | 0.91 | CYP1A2 (1.00) | KIF11CYP1A2CYP2C19HIF1A | |
| SCHEMBL7317503 | 0.91 | KIF11 (1.00) | KIF11CYP1A2CYP2C19HIF1A | |
| SCHEMBL7317508 | 0.90 | KIF11 (0.81) | KIF11CYP1A2CYP2C19HIF1A | |
| SCHEMBL7316099 | 0.87 | KIF11 (0.77) | KIF11CYP1A2CYP2C19HIF1A | |
| SCHEMBL7316096 | 0.87 | KIF11 (0.77) | KIF11CYP1A2CYP2C19HIF1A | |
| SCHEMBL7325876 | 0.87 | KIF11 (0.85) | KIF11CYP1A2CYP2C19HIF1A | |
| SCHEMBL7325870 | 0.87 | KIF11 (0.85) | KIF11CYP1A2CYP2C19HIF1A | |
| SCHEMBL7325988 | 0.86 | KIF11 (0.75) | KIF11CYP1A2CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999041227-A1 | TRICYCLIC COMPOUNDS AS GLYCINE TRANSPORT INHIBITORS | ALLELIX NEUROSCIENCE, INC. (US) | 1999-08-19 | — | — | WO | claimed |
| US-20160287563-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160287563-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160287563-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-9457014-B2 | Cysteine prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9457014-B2 | Cysteine prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9457014-B2 | Cysteine prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160081987-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160081987-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160081987-A1 | Cysteine Prodrugs | PROMENTIS PHARMACEUTICALS, INC. (US) | 2016-03-24 | — | — | US | disclosed |
| EP-2736890-A1 | CYSTEINE PRODRUGS | Promentis Pharmaceuticals, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013016727-A1 | CYSTEINE PRODRUGS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013016727-A1 | CYSTEINE PRODRUGS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| US-6162824-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | ALLELIX NEUROSCIENCE INC. | 2000-12-19 | — | — | US | disclosed |
| WO-1999041227-A1 | TRICYCLIC COMPOUNDS AS GLYCINE TRANSPORT INHIBITORS | ALLELIX NEUROSCIENCE, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287563-A1 | Cysteine Prodrugs | SLC7A11, GCLC, CTH | KIF11 3355/4885CYP1A2 1474/4885CYP2C19 354/4885 |
| US-20160081987-A1 | Cysteine Prodrugs | SLC7A11, GCLC, CTH | KIF11 3355/4885CYP1A2 1474/4885CYP2C19 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.